Theriva Biologics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
TOVX$0.15-7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the year endedDecember 31, | ||||||
| · 2023 · 2022 | ||||||
| Cash Flows From Operating Activities: · · | ||||||
| Net loss | | $(18,349) | | $(19,685) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Stock-based compensation | | 552 | | 475 | ||
| Income tax benefit | | (1,640) | | (1,425) | ||
| Change in fair value of contingent consideration | | | (660) | | | 2,091 |
| Payment of contingent consideration | | | (1,731) | | | — |
| Non - cash lease expense | | | 388 | | | 183 |
| Depreciation | | 135 | | 85 | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | 1,368 | | (363) | ||
| Deposits and other assets | | | (54) | | | — |
| Accounts payable | | (157) | | (385) | ||
| Accrued expenses | | 1,470 | | (267) | ||
| Accrued employee benefits | | 104 | | 333 | ||
| Operating lease liability | | | (422) | | | (124) |
| Net Cash Used In Operating Activities | | (18,996) | | (19,082) | ||
| | | | ||||
| Cash Flows From Investing Activities: | | | ||||
| Purchases of property and equipment | | (202) | | (116) | ||
| Cash paid for business combination; net of cash acquired | | — | | (3,863) | ||
| Pre-acquisition loan to VCN | | — | | (417) | ||
| Net Cash Used In Investing Activities | | | (202) | | | (4,396) |
| | | | | | | |
| Cash Flows From Financing Activities: | | | ||||
| Payment of loans payable | | $(75) | | (1,376) | ||
| Proceeds from issuance under at - the - market offering, net of issuance cost | | | 2,219 | | | — |
| Proceeds from sale of Series C Preferred Stock, net of issuance cost | | | — | | 2,006 | |
| Proceeds from sale of Series D Preferred Stock, net of issuance cost | | — | | 728 | ||
| Payment of contingent consideration | | | (1,519) | | | (3,000) |
| Purchase of treasury stock | | | — | | | (288) |
| Net Cash Provided By (Used In) Financing Activities | | | 625 | | | (1,930) |
| | | | | | | |
| Effects of foreign currency on cash | | | (33) | | | (32) |
| Net decrease in cash and cash equivalents and restricted cash | | | (18,606) | | | (25,408) |
| Cash and cash equivalents and restricted at the beginning of this period | | | 41,885 | | | 67,325 |
| Cash and cash equivalents and restricted cash at the end of this period | | $23,279 | | $41,885 | ||
| | | | | | | |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position | | | | | | |
| Cash and cash equivalents | | | 23,177 | | | 41,786 |
| Restricted cash included in other long-term assets | | | 102 | | | 99 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | | $23,279 | | $41,885 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Right of use assets obtained in exchange for lease liabilities | | $937 | | $— | ||
| Fair value of contingent consideration issued in a business combination | | $— | | $11,093 | ||
| Fair value of equity issued as consideration in a business combination | | $— | | $6,599 | ||
| Effective settlement of pre-closing VCN financing | | $— | | $417 | ||
| Goodwill measurement period adjustment | | $— | | $(1,061) | ||
| In-process R&D measurement period adjustment | | $— | | $810 | ||
| Deferred tax liability measurement period adjustment | | $— | | $202 | ||
| Effect of Warrant exercise price adjustment | | $— | | $340 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.